Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).
von Minckwitz G, Graf E, Geberth M, Eiermann W, Jonat W, Conrad B, Brunnert K, Gerber B, Vescia S, Wollert J, Kaufmann M. von Minckwitz G, et al. Among authors: jonat w. Eur J Cancer. 2006 Aug;42(12):1780-8. doi: 10.1016/j.ejca.2006.04.006. Epub 2006 Jun 12. Eur J Cancer. 2006. PMID: 16765589 Clinical Trial.
A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93.
Kaufmann M, Graf E, Jonat W, Eiermann W, Vescia S, Geberth M, Conrad B, Gademann G, Albert US, Loibl S, von Minckwitz G, Schumacher M; German Adjuvant Breast Cancer Study Group (GABG). Kaufmann M, et al. Among authors: jonat w. Eur J Cancer. 2007 Nov;43(16):2351-8. doi: 10.1016/j.ejca.2007.08.012. Epub 2007 Sep 25. Eur J Cancer. 2007. PMID: 17897821 Clinical Trial.
Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
Kaufmann M, Graf E, Jonat W, Eiermann W, Geberth M, Albert US, Gademann G, Conrad B, Stahl K, von Minckwitz G, Schumacher M; German Adjuvant Breast Cancer Group. Kaufmann M, et al. Among authors: jonat w. J Clin Oncol. 2005 Nov 1;23(31):7842-8. doi: 10.1200/JCO.2005.01.3433. J Clin Oncol. 2005. PMID: 16258087 Clinical Trial.
A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer.
Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, Coates A, Eiermann W, Jänicke F, Njordenskold B, Forbes JF, et al. Jonat W, et al. Eur J Cancer. 1995;31A(2):137-42. doi: 10.1016/0959-8049(94)00415-2. Eur J Cancer. 1995. PMID: 7718316 Clinical Trial.
Survival analyses from the ZEBRA study. goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer.
Kaufmann M, Jonat W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, Schumacher M, Sauerbrei W; Zoladex Early Breast Cancer Research Association (ZEBRA) Trialists' Group. Kaufmann M, et al. Among authors: jonat w. Eur J Cancer. 2003 Aug;39(12):1711-7. doi: 10.1016/s0959-8049(03)00392-7. Eur J Cancer. 2003. PMID: 12888366 Clinical Trial.
Adjuvant randomized trials of doxorubicin/cyclophosphamide versus doxorubicin/cyclophosphamide/tamoxifen and CMF chemotherapy versus tamoxifen in women with node-positive breast cancer.
Kaufmann M, Jonat W, Abel U, Hilfrich J, Caffier H, Kreienberg R, Trams G, Brunnert K, Schermann J, Kleine W, et al. Kaufmann M, et al. Among authors: jonat w. J Clin Oncol. 1993 Mar;11(3):454-60. doi: 10.1200/JCO.1993.11.3.454. J Clin Oncol. 1993. PMID: 8445420 Clinical Trial.
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B; Zoladex Early Breast Cancer Research Association Study. Jonat W, et al. J Clin Oncol. 2002 Dec 15;20(24):4628-35. doi: 10.1200/JCO.2002.05.042. J Clin Oncol. 2002. PMID: 12488406
Adjuvant trastuzumab in HER2-positive breast cancer.
Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J; Breast Cancer International Research Group. Slamon D, et al. N Engl J Med. 2011 Oct 6;365(14):1273-83. doi: 10.1056/NEJMoa0910383. N Engl J Med. 2011. PMID: 21991949 Free PMC article. Clinical Trial.
266 results